Enveric Releases Paper Detailing The Development Of Novel Psilocin Prodrugs For The Treatment Of Mental Health Disorders
Enveric Biosciences, Inc. (NASDAQ: ENVB) has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders. A manuscript describing the research has been submitted for peer-reviewed publication and is currently
